Thursday, November 19, 2026Toronto, ON
The Toronto Journal
Canada

New Designer Opioid With No Generic Name Found in Toronto's Fentanyl Supply, the Sixth New Substance This Year

Toronto's Drug Checking Service first found the orphine-class drug in four samples in October. It has also turned up in Vancouver, and its strength and effects are unknown.

By Journal Staff ·
The red-brick St. Michael's Hospital building in downtown Toronto, with the hospital's name in large white letters on its facade under an overcast sky
St. Michael's Hospital in downtown Toronto, where Toronto's Drug Checking Service is based (file photo, June 2015). Photo: Raysonho / Wikimedia Commons, CC0 (cropped).

A new designer opioid so recent that it doesn't yet have a generic name has turned up in Toronto's street fentanyl. Toronto's Drug Checking Service says it is the sixth new substance found in the city's fentanyl supply so far this year, The Canadian Press reported Thursday.

The drug was first found in four fentanyl samples in October. It has also been detected in Vancouver.

What was found

The service identified the substance as N'-phenethyl-5-chloro nor-orphine or N'-phenethyl-6-chloro nor-orphine. The two compounds are so chemically similar that the service can't currently tell them apart.

It belongs to the orphine class of opioids, a potent group of designer drugs that global monitors are watching more closely. Karen McDonald, executive director of the drug checking service, which operates out of St. Michael's Hospital, said there is next to no research on the new drug, so its strength and effects are unknown.

"This is a really good example of what we're dealing with, with the unregulated fentanyl supply. It is just evolving, and the substances that are presenting are incredibly novel," McDonald said.

It isn't the first orphine in Toronto. Late last year, the service started finding cychlorphine, an orphine believed to be about 10 times stronger than fentanyl. In an April bulletin, Ontario's Drug Checking Community said it had found orphines in opioid samples from Toronto and Thunder Bay, and noted that because orphines are opioids, naloxone should reverse their effects in an overdose.

A supply that rarely matches the label

Cristiana Stefan, a lab director and clinical biochemist at the Centre for Addiction and Mental Health, is worried about how the new orphine might interact with other drugs. "It's never good news whenever there is something else in the supply," she said. Her team, which analyzes the samples collected by the service, spent weeks trying to identify the unknown substance in October's samples.

Drugs sold as fentanyl in Toronto are often mixed with other substances. In the service's latest report, 96 per cent of "fentanyl" samples were cut with at least one non-opioid drug, usually a veterinary tranquillizer or a benzodiazepine. In the same period, 83 per cent contained more than one high-potency opioid, and more than a quarter contained all three: a high-potency opioid, a vet tranquillizer and a benzodiazepine.

Across the country, more overdose deaths involve several substances. The Public Health Agency of Canada found that the share of opioid or stimulant overdose deaths involving three or more substances rose to 42 per cent in 2023, up from 20 per cent in 2018. That's an increase from 491 deaths to more than 1,500.

Why the recipe keeps changing

McDonald said the fentanyl supply was far less contaminated when the service first launched. She said drug laws and scheduling affect which precursor chemicals are available. As governments try to keep up with new opioids, producers invent new ones to cut risk and cost.

Dan Werb, a substance use epidemiologist at St. Michael's Hospital, said producers also change their recipes based on how users react. "There's an incentive for drug traffickers to produce these higher-potency opioid products. They test them, they introduce them, they see what happens. If too many people die, they remove them, maybe they reduce the potency and the cycle continues," he said.

He pointed to carfentanil, about 100 times more potent than fentanyl. Federal data show it was involved in 20 per cent of apparent opioid overdose deaths in 2019 and three per cent in 2024. Werb said lower potency in the illicit supply has been a key reason overdose deaths in Canada have declined since 2023.

But he warned that could change. "What keeps me up at night is the fact that we do not control these markets. At any time, new products could be introduced," he said.

Earlier this year, a CBC News analysis found sharp increases in paramedic calls for opioid overdoses in Ottawa, Toronto, Thunder Bay and Hamilton from January to May, compared with the same period in 2025. The data don't explain why. Researchers, health workers and advocates have pointed to the toxic drug supply and to supervised consumption site closures over the past two years as possible factors.

Sources: CBC News / The Canadian Press (Nov. 19) · The Canadian Press via Global News (Nov. 19) · CTV News Toronto (video, Nov. 19) · Ontario's Drug Checking Community bulletin on orphines (April 7)